Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection

Alimentary Pharmacology & Therapeutics

Volumn 9, Issue 2, 1995, Pages 209-212

  YOUSFI, M M ^a   EL ZIMAITY H M T ^a,b   AL ASSI M T ^a   COLE, R A ^a   GENTA, R M ^a,b   GRAHAM, D Y ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; GASTROINTESTINAL INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; TASTE DISORDER;

ADULT; AGED; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; MALE; METRONIDAZOLE; MIDDLE AGE; OMEPRAZOLE; SUPPORT, U.S. GOV'T, NON-P.H.S.; TREATMENT OUTCOME;

EID: 0028924556     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1995.tb00374.x     Document Type: Review

References (30)

1. Drug therapy for Helicobacter pylori infection: problems and pitfalls
2. Helicobacter pylori
3. The who's and when's of therapy for Helicobacter pylori
4. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease
5. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease
6. Helicobacter pylori and metronidazole resistance
7. Adjuvant therapy in duodenal ulcers treated with colloidal bismuth subcitrate
8. Metronidazole resistance in Helicobacter pylori
9. Metronidazole‐resistant Helicobacter pylori
10. Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination
11. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones
12. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics
13. Eradication of Helicobacter pylori with clarithromycin and omeprazole
14. Clarithromycin, tetracycline and bismuth: a new non‐metronidazole therapy for Helicobacter pylori infection
15. Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection
16. Omeprazole as an adjuvant to antimicrobial therapy for eradication of Helicobacter pylori infection
17. Clarithromycin‐amoxycillin therapy for Helicobacter pylori infection
18. Clarithromycin and omeprazole in the prevention of duodenal ulcer and eradication of H. pylori
19. An evaluation of 10 days clarithromycinomeprazole‐bismuth
20. Comparison of two different triple therapies with clarithromycin for Helicobacter pylori eradication
21. Amoxicillin‐clarithromycin‐omeprazole: the best therapy for Helicobacter pylori infection
22. Efficacy of a new one week triple regime in eradicating Helicobacter pylori
23. Effect of omeprazole and clarithromycin plus tinidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer
24. Clarithromycin and omeprazole for Helicobacter pylori
25. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain
26. In vivo susceptibility of Campylobacter pylori
27. There are discrepancies between the results of antimicrobial susceptibility testing of Helicobacter pylori using E‐test compared to broth microdilution or disk diffusion
28. The role of infectious agents in peptic ulcer disease
29. Prevalence of metronidazole‐resistant Helicobacter pylori in dyspeptic patients
30. Omeprazole‐tetracycline combinations are inadequate as therapy for Helicobacter pylori infection